CLINICAL TRIAL NEWS

Here you will find news and webinars related to Huntington Disease clinical trials and studies.

2025

October 24th, 2025

Community Update:

SOM Biotech has secured a clear FDA path for SOM3355 in Huntington’s disease — a significant milestone paving the way toward Phase 3 and potential new treatment options for the community.
In our latest article, Astri Arnesen and Dina de Sousa break down what this means for patients, families, and the future of HD research.
 
 

Learn more

October 10th, 2025

Community Update:

We break down the new AMT-130 results — what the data shows, why it matters, and what this could mean for the future of Huntington’s disease research.

Read more

September 24th, 2025

Positive news for the HD Community!

uniQure announced today the results for the Phase I/II Study of AMT-130 for the treatment of patients with HD. The study met its prespecified primary endpoint, with high-dose AMT-130 demonstrating a statistically significant slowing of disease progression as measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) at 36 months compared to a propensity score-matched external control.

Press release

September 18th, 2025

Promising Results for New HD Drug SKY-0515

Skyhawk Therapeutics has shared encouraging early trial results for SKY-0515, an experimental pill being studied for Huntington’s disease. The drug reached the brain well, was safe so far, and is now moving into a larger Phase 2/3 trial with 120 participants in Australia and New Zealand.

Read more

Press release

September 3rd, 2025

Learning from Sweden's Multidisciplinary HD Care

During our annual team meeting in Sweden, we visited the HD Clinic at Skåne University Hospital, in Lund.

We met Professor Åsa Petersén and nurse Camilla Svensson, and saw firsthand how their multidisciplinary team combines research with compassionate care 💙

Read  more

August 28th, 2025

Simplifying Science: What Causes Huntington's Disease?

In this new series, we want to take a deep dive into scientific concepts in a simple way, with the goal of eventually bringing research concepts closer to all of you.

This first article will be dedicated to understanding the hereditary nature of HD.

We hope this information explains well most of the aspects of the genetic and hereditary nature of HD. Stay tuned because in our next article we will keep simplifying science and taking a closer look at the neurodegenerative process!

Read more

August 21st, 2025

Novartis is planning a phase 3 trial of Votoplam

Exciting news for the HD community
Novartis has announced plans to move forward with a Phase 3 clinical trial based on encouraging results from their Phase 2 study. This marks an important step in the search for new treatments for Huntington’s disease.
 
 

July 25th, 2025

Prilenia and Ferrer provide update on European regulatory process for Pridopidine in Huntington's Disease

Today, Prilenia and Ferrer shared disappointing news: the EMA’s advisory body has given a negative opinion on the approval of pridopidine for HD.
However, this is not the end of the road. They are exploring all regulatory options, including the possibility to request a re-examination in the next two weeks.
Looking ahead, Prilenia has announced plans to launch a new global Phase 3 study, building on all the knowledge and insights gathered so far.
We understand this is disappointing news for our community. We will continue to follow developments closely and keep you updated.

May 6th, 2025

PTC Press Release Explained: What It Means for Our Community | May 2025 Update

Astri Arnesen and Dina de Sousa take a closer look at PTC Therapeutics’ press release, highlighting what the latest updates mean for people affected by Huntington’s disease.

In this video, they explain the main findings in a way that’s easy to follow and emphasize why this development brings hope to the community.

It’s a great starting point for understanding the news — and we encourage everyone to read the full press release for all the scientific details.

May 5th, 2025

PTC518 PIVOT-HD Study Achieves Primary Endpoint

Big news from PTC Therapeutics! PTC has announced important updates on their investigational treatment for Huntington’s Disease, paving the way for next steps in clinical development.

Press release

April 29th, 2025

PRILENIA AND FERRER PARTNER TO ADVANCE PRIDOPIDINE IN EUROPE AND SELECT MARKETS

Prilenia has entered into a significant collaboration with Ferrer to commercialize and further develop pridopidine in Europe and select markets. Pridopidine is a potent and highly selective  orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD.

Watch video

April 17th, 2025

uniQure’s Gene Therapy for Huntington’s Disease Receives Special FDA Designation

The FDA has granted Breakthrough Therapy Designation to uniQure’s gene therapy, AMT-130, for Huntington’s disease. This means the data so far looks very promising, and the therapy will now have faster access to review when full results are available. A hopeful step forward for the HD community!

Read more

Press release

April 17th, 2025

UPDATE ON THE PHASE II GENERATION HD2 STUDY

Roche has provided an interim update on the Phase II GENERATION HD2 clinical trial, which is evaluating the investigational drug tominersen in individuals with early or very subtle signs of HD. Read the full article to learn more

Read more

Community Letter

February 6th, 2025

SOM Biotech presents the Phase 2b study results with SOM3355 demonstrating

Exciting News from SOM Biotech! 🚨
SOM Biotech has shared very positive results from their Phase 2 trial of SOM3355 for Huntington’s disease chorea. This drug, previously used for other conditions, has shown significant improvement in motor symptoms with minimal side effects.
💜 Thanks to everyone who participated in the trial! This brings us one step closer to better treatment options for the HD community.
 
 

2024

December 10th, 2024

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Uniqure releases updates about AMT-130’s approval pathway.
The pharmaceutical company has made key progress in its pursuit of Accelerated Approval for AMT-130, a gene therapy for Huntington’s Disease, by reaching alignment with the FDA on key elements.
🎯 Highlights:
– Agreement on Relevant Data: FDA has agreed that data from the Phase I/II studies, compared to a natural history external control, may serve for an upcoming regulatory submission known as Biologics License Application (BLA).
– Clinical Measures Validated: The FDA recognizes the composite Unified Huntington’s Disease Rating Scale (cUHDRS) as a valid intermediate clinical endpoint for the Accelerated Approval Process.
– Supporting Evidence: Reductions in neurofilament light chain (NfL) levels in cerebrospinal fluid (CSF) may serve as supportive evidence for therapeutic claims.
– Regenerative Medicine Advanced Therapy (RMAT) Status: Confirmed in May 2024, highlighting AMT-130’s potential to meet critical unmet needs in HD treatment.
 

November 12th, 2024

FDA SHOWS INITIAL SUPPORT FOR WVE-003

This morning, Wave Life Sciences reported that they have received supportive initial feedback from FDA on WVE-003. They engaged the FDA following their positive SELECT-HD clinical results, and today, they announced that the FDA recognize the severity of HD and have indicated they are open to our plan to evaluate biomarkers, including caudate atrophy, as an endpoint to assess HD progression with the potential to predict clinical outcomes. FDA also granted WVE-003 Orphan Drug Designation last week.

Wave is now planning activities for an efficient global, potentially registrational Phase 2/3 study of WVE-003 and planning for an Investigational New Drug submission for this study in the second half of 2025.

Read the Press release

 

October 30th, 2024

Webinar: Research Insights: Latest Updates on Ongoing Studies​

On October 23rd, the European Huntington Association  held an engaging and informative webinar titled “Research Insights: Latest Updates on Ongoing Studies.”

The webinar provided a comprehensive overview of the latest developments in clinical trials, with each company sharing updates and preliminary insights from their ongoing or completed studies in HD treatment.

These presentations underscored the diversity of approaches and the progress being made across therapeutic areas. 

Watch webinar

Read more

September 26th, 2024

FDA Grants Fast Track Designation to PTC518 Huntington's Disease Program

Exciting News! 📢
The FDA has granted Fast Track designation to PTC Therapeutics’ PTC518, an investigational treatment for Huntington’s disease. This marks a major step forward in the fight against HD, accelerating the development and review process.
 

July 9th, 2024

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure reports promising interim results from Phase I/II trials of AMT-130 for Huntington’s disease, showing an 80% slowing of disease progression at high doses and significant reduction in neurodegeneration markers at 24 months.
🔬 The FDA granted RMAT designation, signaling potential for expedited development.
 

June 25th, 2024

Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease

Exciting News for the Huntington’s Disease Community!
📢 Wave Life Sciences announced positive results from their SELECT-HD Phase 1b/2a trial of the investigational therapy WVE-003 for Huntington’s disease.
The trial showed that WVE-003 selectively lowers the toxic mutant huntingtin (mHTT) protein while preserving the healthy wild-type huntingtin (wtHTT) protein.
 

June 20th, 2024

Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients

🙌 PTC Therapeutics today announced promising 12 month results from their Phase 2 PIVOT-HD study of oral PTC518.
At Month 12, mutant Huntingtin (mHTT) in the blood was lowered by 22% and 43% respectively for 5mg and 10mg doses. A similar result was seen in cerebrospinal fluid, where mHTT was lowered by 21% and 43% respectively, for 5mg and 10mg doses.
👉In addition PTC518 treatment resulted in a notable slowing in progression of motor symptoms at month 12, as assessed by the Total Motor Score (2.0 points worsening for 5mg and 1.3 points worsening for 10mg vs. 4.9 points worsening for placebo).
 

June 3rd, 2024

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

🙌Uniqure’s gene therapy for Huntington’s Disease, named AMT-130 has passed a significant next step.

The company announced that the US regulators, FDA, has granted them a Regenerative Medicine Advanced Therapy (RMAT) designation.

Read more

Press release

March 12th, 2024

NEW WEBINAR VIDEO AVAILABLE: Prilenia filing for EMA approval for Pridopidine - What does this mean for patients?

Watch our webinar with Henk Schuring, Chief Regulatory and Commercialization Officer at Prilenia, and Anne Rosser, Professor at Cardiff University, where we had the opportunity to better understand what Prilenia’s request for EMA’s (European Medicines Agency) approval of Pridopidine means for the Huntington’s Disease community.

Watch the webinar video

Read more

March 12th, 2024

Prilenia will ask for market approval at the European Medicines Agency for Pridopidine (an oral drug) in Huntington’s Disease.

Today, Prilenia made a groundbreaking announcement, revealing that they are going to apply for market authorization at the European Medicines Agency (EMA) within the next few months. 💪This marks a historic moment as the first-ever medicine for Huntington’s Disease (HD) reaches this critical stage.

🙌 We think this is a day to celebrate. However, we fully realise this is not the end of the journey. submitting an application to the EMA and the review process takes time, and can have both a positive or a negative output. In collaboration with Prilenia we are organizing a Webinar, to provide us all with a more in-depth understanding of the rationale behind the decision to apply for market approval and what it means for patients.

Read more

January 9th, 2024

Watch now the Webinar video: Why do we need a second Generation HD trial?

The European Huntington Association, in collaboration with Roche, organized a webinar on January 9th to discuss the updates on the GENERATION HD2 clinical trial and address all the questions about why this trial is needed.

With 70 trial sites activated worldwide and over 30% of the trial enrolment, GENERATION HD2 clinical trial is on the right path. But we need to speed up to have the trial fully recruited as soon as possible to get the results. The trial aims to explore the effect on biomarkers and function in the 300 participants, all in early phases of HD and in the age between 25 and 50. 

Listen to Professor Sarah Tabrizi (UCL) and Doctor Peter McColgan (MD PhD) from Roche talking about the latest updates on GENERATION HD2 trial.

Watch the Webinar video

2023

November 29th, 2023

Webinar for the nordic countries: HS forskningsoppdateringer for de nordiske landene

On the 22nd of November, the European Huntington Association and the Moving Forward team, in collaboration with the Norwegian HD Association and the Swedish HD Association, organized a Webinar on HD research updates for the Nordic Countries. The webinar is in Norwegian.

There were just over 70 participants from Norway, Sweden, Denmark, and Finland.

We were joined by Astri Arnesen, Lasse Pihlstrøm and Åsa Petersen to talk about what is happening in HD research globally and what is happening specifically in Norway and Sweden.

Watch the Webinar video

June 21st, 2023

uniQure Announces Update on AMT-130 study for the Treatment of Huntington’s Disease

The treatment tested in the AMT130 trial is well tolerated and Patients treated with AMT-130 show preserved function compared to when they started in the trial (baseline) and clinical benefits relative to the natural history of the disease. These are some of the results announced by UniQure in a press release.

In essence, this means that there are signs that the treatment works and slow down the progression of the disease. UniQure is re-encouraged by the results and plans to continue and extend the program

Read the press release here

Read the HD community letter

June 9th, 2023

2023 Community Survey - Understanding The Needs Of Young People Impacted By HD

The ultimate goal of this survey is to learn how the HDYO can meet these needs, so that it can support, educate and empower the young people from HD families across the globe. Thus, the results of this study will provide understanding about the needs of people impacted by HD and inform the types of support provided by HDYO.

Complete the survey here

June 9th, 2023

JOIN-HD – The Global Registry for Juvenile onset Huntington’s Disease

JOIN-HD is a worldwide registry for families affected by Juvenile onset Huntington’s Disease (JoHD), which aims to shed light on this diagnosis, bring together those impacted by JoHD, increase awareness and knowledge about this condition, facilitate research and help advocate for better care.

Learn more about the trial here

May 12th, 2023

WEBINAR VIDEO 🟢 PROOF-HD study good and less good news

On April 25th, Prilenia announced results from the PROOF-HD clinical trial for Huntington’s Disease. Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all.

The European Huntington Association, in collaboration with Prilenia, organized a Webinar to talk about the preliminary study results from the phase 3 PROOF-HD study and what they mean.

Listen to Dr Michael Hayden (founder and CEO of Prilenia), Dr Ralf Reilman (Principal Investigator for PROOF-HD in Europe) and Dr. Andrew Feigin (Chair at The Huntington Study Group) explaining the results and indicating further steps. 

Watch the Webinar video here

May 11th, 2023

There has been an amendment to the PIVOT HD trial entry criteria

We just updated the inclusion criteria for PIVOT HD, the PTC Therapeutics Phase II clinical trial. 

  • Length of trial from 12 weeks to 12 months
  • CAG repeat length was previously 42-50 and is now 40-50
  • Number of subjects was previously 162 an is now up to 252
  • We are recruiting Stage II AND Stage 3 now (so TFC and/or Independence scale less than 13/100)

Learn more about the trial here

April 25th, 2023

Prilenia announce results from the PROOF-HD study

Prilenia announce results from the PROOF-HD study: Promising, but mixed results!
Some of the participants showed significant benefits from the Pridopidine drug, while others did not benefit at all. This is promising because, for the first time, we have a drug that demonstrates effect on disease progression, cognitive and motor symptoms.

After the announcement, the European Huntington Association organized a Webinar with Dr Michael Hayden, founder and CEO of Prilenia, who will explain the results and indicate further steps. 

March 20th, 2023

WEBINAR VIDEO: Novartis Discusses the VIBRANT-HD Trial

The European Huntington Association, in collaboration with Novartis, organized a Webinar to learn more about VIBRANT-HD trial and the decision to stop the development of branaplam in Huntington’s Disease.

The webinar speakers included VIBRANT-HD clinical site investigator and Steering Committee member, Bernhart Landwehrmeyer, Medical lead for the branaplam program, Dr. Harry Ramos, and Clinical program head for the branaplam program, Dr. Beth Borowsky.

Watch the full webinar here

January 19th, 2023

WEBINAR: Updates of Wave's clinical trial SELECT-HD

The European Huntington Association, in collaboration with Wave, organized a Webinar on the updates of Select-HD clinical trial for Huntington’s disease.

Dr. Ralf Reilmann, founder of the George-Huntington Institute in Muenster, presented an overview of the SELECT-HD trial, which is looking at the safety of the investigational molecule called WVE-003. After his presentation, we had a Q&A session with Danlin Xu, HD Medical Director at Wave, and Marissa Volpe, HD Program Lead at Wave.

Watch the full webinar here

January 12th, 2023

WEBINAR: Updates from Roche on Phase II GENERATION HD2 study for Huntinton's Disease

The GENERATION HD2 clinical trial is just about to start recruiting participants in the first of a total of 15 countries and 9 of them are in Europe: Denmark, France, Germany, UK, Poland, Italy, Spain, Portugal and Switzerland. The study aims to enroll 360 participants and evaluate the safety of the investigational drug tominersen in people with early manifest HD.

Watch here the webinar video

January 11th, 2023

EFNA's new eLearning initiative on research

The online course aims to upskill participants on how they can effectively advocate in a virtual world by identifying and engaging key stakeholders and developing partnerships, hosting successful online events and developing and disseminating key advocacy messages.

Learn more about it here

December 16th, 2022

Updates from SOM Biotech

We met with Dr Catherine Scart, Chief Medical Officer at Som Biotech, and we asked her some questions about the new Phase 2b trial for Huntington’s Disease (HD) called SOM3355.

Watch the video here

2022

December 12th, 2022

We moved VIBRANT-HD to the completed trials section

Novartis ends the VIBRANT-HD study and will not continue the program with Branaplam. 

Read the EHA article and the Novartis letter here

December 11th, 2022

Check our new Webinar section!

We have compiled all the European Huntington Association recent webinars in a new section that you can find in the menu of the webpage.

Find it here

December 11th, 2022

We have adapted the HDTrial Finder dictionary to make it easier and more convenient by including it on the different clinical trial pages. Simply click on the highlighted words to find an easy definition.

new FB feed (19)

dictionary:

SNP-single nucleotide polymorphisms

a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.

 
new FB feed (19)

dictionary:

at risk

You do not know if you carry the genetic mutation for HD gene 

 
new FB feed (19)

dictionary:

TFC-total functional capacity

A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity. 

 
new FB feed (19)

dictionary:

Double-blinded

 means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.

new FB feed (19)

dictionary:

Open label

A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.

new FB feed (19)

dictionary:

Gene therapy

a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.

new FB feed (19)

dictionary:

UHDRS- Unified Huntington Disease Rating Scale

A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD

new FB feed (19)

dictionary:

CAG repeat

The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD

new FB feed (19)

dictionary:

Wild-type

the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein

new FB feed (19)

dictionary:

Tolerabilty

How well a person can handle a treatment without having serious or uncomfortable side effects.

new FB feed (19)

dictionary:

Striatum

Part of the brain that  coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.

new FB feed (19)

dictionary:

Randomized allocation

A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

new FB feed (19)

dictionary:

Radioligand

a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity

new FB feed (19)

dictionary:

Protein

Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.

new FB feed (19)

dictionary:

Premanifest / Prodromal

Prior to onset or diagnosis of movement symptoms.

new FB feed (19)

dictionary:

Placebo

A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.

new FB feed (19)

dictionary:

PK - Pharmacokinetics

The movement of drugs through the body

new FB feed (19)

dictionary:

PD - Pharmacodynamics

The body’s biological response to drugs

new FB feed (19)

dictionary:

PET scan

Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.

new FB feed (19)

dictionary:

Neuron

Brain cells that store and transmit information

new FB feed (19)

dictionary:

MRI

Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones 

new FB feed (19)

dictionary:

mHTT

Mutant huntingtin protein. The protein produced by the faulty HD gene.

new FB feed (19)

dictionary:

Manifest

after HD diagnosis, or when symptoms are already showing

new FB feed (19)

dictionary:

Longitudinal study

A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once

new FB feed (19)

dictionary:

HTT

one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15

new FB feed (19)

dictionary:

fMRI

functional MRI:As with MRI, a technique using powerful magnetic fields  but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes

new FB feed (19)

dictionary:

CSF - cerebrospinal fluid

A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.

new FB feed (19)

dictionary:

Efficacy

A measure of whether a treatment works or not

new FB feed (19)

dictionary:

ASO(Antisense oligonucleotides)

A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene

new FB feed (19)

dictionary:

Biomarker

a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable

new FB feed (19)

dictionary:

BDNF

Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.

new FB feed (19)

dictionary:

Allele

one of the two copies of a gene

new FB feed (19)

dictionary:

Plasma

Liquid component of the blood.

new FB feed (19)

dictionary:

Gene

The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.

new FB feed (19)

dictionary:

Phase

Clinical trial phases are different stages of research that assess the safety and effectiveness of a new medical treatment or intervention in humans.

Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.